公告提醒：愛(ài)必信所有產(chǎn)品和服務(wù)僅用于科學(xué)研究，不用于臨床應(yīng)用及其他用途提供產(chǎn)品和服務(wù)（也不為任何個(gè)人提供產(chǎn)品和服務(wù)）!

抑制劑描述：

產(chǎn)品名稱：Vorinostat (SAHA)

產(chǎn)品別名：伏立諾他

英文別名：SAHA;MK0683;suberoylanilide hydroxamic acid

靶點(diǎn)：HDAC

CAS：149647-78-9

純度：>98%

外觀：白色至類(lèi)白色結(jié)晶粉末

保存方法：store at -20℃ for one year（Powder）； in DMSO or others solvent store at 2-4℃ for two weeks, at -80℃ for six months.

描述：

Vorinostat (SAHA) is an HDAC1/3 inhibitor with IC50 of ~10 nM.

溶解性：DMSO ：53 mg/mL (200.52 mM)
Ethanol ：3 mg/mL (11.35 mM)

體外研究：

Vorinostat inhibits the activities of HDAC1 and HDAC3 with IC50 of 10 nM and 20 nM, respectively. Vorinostat also results in a marked hyperacetylation of histone H4. Vorinostat inhibits the growth of three prostate cancer cell lines LNCaP, PC-3 and TSU-Pr1 at micromolar concentrations (2.5-7.5 μM), and induces dose-dependent cell death in LNCaP cells. Vorinostat treatment in MCF-7 cells inhibits cell proliferation at an IC50 of 0.75 μM resulting in the accumulation of cells in the G1 and G2-M phase of the cell cycle. Vorinostat also induces differentiation in the estrogen receptor-negative cell line SKBr-3 and the retinoblastoma-negative cell line MDA-468. Vorinostat treatment at 1 μM for 8 hours or more is sufficient to irreversibly induce apoptosis of human multiple myeloma (MM) cells. The gene expression profiles of Vorinostat treated MM cells are not hallmarked by global transcriptional activation, but by coordinated transcriptional changes of specific functional groups of genes such as cytokine-induced proliferative/survival signaling cascades, oncogenes-tumor suppressor genes, regulators of apoptosis, DNA synthesis-repair and cell cycle, and proteasome-ubiquitin function.

體內(nèi)研究：Administration of Vorinostat (~100 mg/kg/day) significantly inhibits the growth of CWR22 human prostate xenografts in nude mice with tumor reductions of 78%, 97% and 97%, at doses of 25 mg/kg/day, 50 mg/kg/day and 100 mg/kg/day, respectively, compared with control. Vorinostat induces the accumulation of acetylated core histones and prostate-specific antigen mRNA expression in CWR22 cells, resulting in higher levels of serum prostate-specific antigen than predicted from tumor volume alone. Oral administration of Vorinostat (0.67g/L) crosses the blood-brain barrier, increases histone acetylation in the brain, and dramatically improves the motor impairment in the R6/2 mice model of Huntington's disease.

產(chǎn)品信息訂購(gòu)：

產(chǎn)品更多信息請(qǐng)進(jìn)入愛(ài)必信網(wǎng)站咨詢